What is the current stock price of Global X China Biotech Innovation ETF (CHB)?

As of the latest market data, Global X China Biotech Innovation ETF (CHB) is trading at $6.64. The stock has seen a loss of -0.38% today.

Does Global X China Biotech Innovation ETF (CHB) pay a dividend?

Based on current data, Global X China Biotech Innovation ETF does not have a confirmed active dividend policy.

What is the market cap of Global X China Biotech Innovation ETF?

The current market capitalization of Global X China Biotech Innovation ETF (CHB) is approximately unavailable.

CHB

Global X China Biotech Innovation ETF·Financial Services

6.64

0.375%(−0.03)

Close Price

Last Updated: — ET

52W L: $6.6352W H: $9.76

CHB NEWS

globenewswire.com

Mar 17

Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) for Hydronidone (F351) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). This decision by CDE was made following the pre-NDA communication meeting previously announced on January 5, 2026 and is a major milestone in the NDA process.

Company Profile

The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China’s biotechnology industry. It is non-diversified.

Sector

Financial Services

Industry

Asset Management

IPO Date

2020-09-25

Beta

0.66